Patents by Inventor Louis Nickolaus Jungheim

Louis Nickolaus Jungheim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE
    Publication number: 20140031287
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 20, 2013
    Publication date: January 30, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 8552039
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: October 8, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeil McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide
    Patent number: 8546581
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: October 1, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John Mcneill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20110190205
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 4, 2011
    Applicant: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus JUNGHEIM, John McNeill MCGILL, III, Kenneth Jeff THRASHER, Robert Jason HERR, Muralikrishna VALLURI
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 7947841
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: May 24, 2011
    Assignee: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Valluri Muralikrishna
  • COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE
    Publication number: 20100120876
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: December 11, 2009
    Publication date: May 13, 2010
    Applicant: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Robert Jason HERR, Louis Nickolaus JUNGHEIM, John McNeill MCGILL, III, Kenneth Jeff THRASHER, Muralikrishna VALLURI
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 7662771
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: February 16, 2010
    Assignee: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20090239798
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Application
    Filed: November 3, 2008
    Publication date: September 24, 2009
    Applicant: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20080214448
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 18, 2004
    Publication date: September 4, 2008
    Applicant: EMISPHERE TECHNOLOGIES INC.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Triazole derivatives as tachykinin receptor antagonists
    Patent number: 7320994
    Abstract: This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Brian Stephen Muehl, David Michael Remick, Michael Alan Robertson, Kenneth Allen Savin
  • Tachykinin receptor antagonists
    Patent number: 7179804
    Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: February 20, 2007
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Michael Alan Robertson, Kenneth Allen Savin
  • Substituted dipeptides as growth hormone secretagogues
    Patent number: 7125840
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher
  • Compounds and pharmaceutical compositions for inhibiting MRP1
    Patent number: 7101891
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Compounds and methods for inhibiting MRP1
    Patent number: 7037921
    Abstract: The present invention relates to a compound of Formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Louis Nickolaus Jungheim, Kenneth Jeff Thrasher
  • Growth hormone secretagogues
    Patent number: 6992097
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Ring modified cyclic peptide analogs
    Patent number: 6939946
    Abstract: A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: September 6, 2005
    Assignee: Eli Lilly and Company
    Inventors: Peter Stanley Borromeo, Jeffrey Daniel Cohen, George Stuart Gregory, Stacy Kay Henle, Stephen Andrew Hitchcock, Louis Nickolaus Jungheim, Daniel Ray Mayhugh, Timothy Alan Shepherd, William Wilson Turner, Jr.
  • Growth Hormone secretagogues
    Publication number: 20040122234
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: June 3, 2003
    Publication date: June 24, 2004
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Compounds and pharmaceutical compositions for inhibiting mrp1
    Publication number: 20040116460
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: September 25, 2003
    Publication date: June 17, 2004
    Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Substituted dipeptides as growth hormone secretagogues
    Publication number: 20040058971
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for usein the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: March 14, 2003
    Publication date: March 25, 2004
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher